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Abstract
Background: Cerebral ischaemia initiates an inflammatory response in the brain and periphery.
We assessed the relationship between peak values of plasma interleukin-6 (IL-6) in the first week
after ischaemic stroke, with measures of stroke severity and outcome.
Methods: Thirty-seven patients with ischaemic stroke were prospectively recruited. Plasma IL-6,
and other markers of peripheral inflammation, were measured at pre-determined timepoints in the
first week after stroke onset. Primary analyses were the association between peak plasma IL-6
concentration with both modified Rankin score (mRS) at 3 months and computed tomography
(CT) brain infarct volume.
Results: Peak plasma IL-6 concentration correlated significantly (p < 0.001) with CT brain infarct
volume (r = 0.75) and mRS at 3 months (r = 0.72). It correlated similarly with clinical outcome at
12 months or stroke severity. Strong associations were also noted between either peak plasma C-
reactive protein (CRP) concentration or white blood cell (WBC) count, and all outcome measures.
Conclusions: These data provide evidence that the magnitude of the peripheral inflammatory
response is related to the severity of acute ischaemic stroke, and clinical outcome.
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Background
Cerebral ischaemia initiates an inflammatory response in
the brain [1] that is associated with induction of a variety
of cytokines, including interleukin-6 (IL-6), a pleiotropic
cytokine involved in diverse inflammatory functions. IL-6
mRNA and bioactivity are induced rapidly in experimen-
tal focal cerebral ischaemia [2,3], and elevated IL-6 con-
centrations in cerebrospinal fluid (CSF) of acute stroke
patients correlate with infarct volume [4]. However, the
role of IL-6 in the central nervous system (CNS) following
experimental cerebral ischaemia is not resolved [2,3,5,6].
Systemic inflammatory responses are also evident follow-
ing inflammation in the CNS, but the relationship
between peripheral mediators and CNS events is uncer-
tain [7]. Peripheral infection, which commonly precedes
or complicates stroke [8,9], is also a major stimulus for
production of cytokines and an acute phase response.
Although most cytokines are only present at biologically
effective concentrations at the site of inflammation, IL-6 is
a major circulating cytokine produced in response to
inflammatory insult and infection, and is a potent stimu-
lus for production of hepatic acute phase proteins [10],
induction of fever [11], and activation of the hypotha-
lamic-pituitary-adrenal (HPA) axis [12].
The relationship between peripheral inflammatory mark-
ers and outcome in stroke patients remains poorly under-
stood. In patients with acute ischaemic stroke, some
studies have reported an association between circulating
IL-6 concentration and brain infarct volume, stroke sever-
ity, or outcome up to 6 months [13-17]. Conversely, other
studies have reported no association between serum IL-6
concentration and infarct volume or stroke severity at 3
months [4,18]. Other markers of the acute phase response
have also been implicated in the pathophysiology and
outcome following ischaemic stroke [19-26]. However,
very few studies have related the magnitude of the periph-
eral inflammatory response in the first week to measures
of severity of ischaemic insult or clinical outcome.
We have recently reported the kinetics of peripheral
inflammatory markers in ischaemic stroke patients pro-
spectively recruited within 12 hours of symptom onset,
compared to controls matched for age, sex and degree of
atherosclerosis [27]. The aim of the present study was to
examine the relationship between the magnitude of the
peripheral inflammatory response, as determined by peak
values of plasma IL-6 or other peripheral inflammatory
markers (peak plasma C-reactive protein (CRP), white
blood cell (WBC) count, erythrocyte sedimentation rate
(ESR), plasma cortisol concentration and aural tempera-
ture) in the first week of stroke, with either severity of
ischaemic insult, or long-term outcome.
Subjects and methods
The study was approved by the Local Research Ethics
Committee. Consecutive patients aged over 18 years pre-
senting with a clinical diagnosis of acute stroke, with sus-
pected symptom onset within the preceding 12 hours,
were screened prospectively. Patients were excluded if the
time of symptom onset could not be reliably determined
from the patient or witness. Patients with rapid improve-
ment of symptoms between onset and screening, or evi-
dence of active malignancy, were also excluded. Written
informed consent was obtained from all patients
recruited, or written assent from a relative. Clinical his-
tory, examination, medications and Oxfordshire Commu-
nity Stroke Project (OCSP) classification [28] were
recorded at baseline. Computed tomography (CT) brain
scan (IGE CT Pace Plus 3rd generation scanner, IGE Medi-
cal Systems Ltd, Milwaukee, WI) was performed within 24
hours of admission to exclude patients with stroke mimic
or primary intracerebral haemorrhage (PICH). Blood
pressure, pulse rate and aural temperature (Braun Ther-
moscan LF20 digital thermometer) were recorded at all
visits. At 3 and 12 months, additional medical history,
changes in medication history and general clinical exami-
nation were also recorded. Infections were recorded pro-
spectively during the study period wherever possible,
using all available clinical information and investigation
results. In the case of suspected infections preceding the
index stroke, information was gathered from history and
clinical records.
Blood sampling and determination of peripheral 
inflammatory markers
Venous blood was drawn by venepuncture at study entry,
next day at 09:00, 24 hours (if presentation was not
between 07:00 and 11:00) and 5 to 7 days. Blood was col-
lected in tubes containing EDTA (Sarstedt, UK) for analy-
sis of ESR using an automated Westergren method
(Starrsed 3, Mechatronics, Holland; supplied by Vitech
Scientific, UK) and total WBC count using the Coulter
principle method (Beckman-Coulter GEN-S, Florida,
USA). The remaining blood for plasma IL-6, CRP and cor-
tisol analysis was transferred to heparinised tubes, stored
in cooled gel packs for one hour, and centrifuged at 2000
g for 30 minutes at 4°C. Plasma was separated, frozen and
stored at -70°C until analysis. Plasma IL-6 was measured
using a sandwich enzyme-linked immunosorbent assay
(ELISA), plasma CRP using a competitive, high-sensitivity
ELISA, and plasma cortisol using a solid phase time-
resolved fluroimmunoassay (DELFIA®, Perkin Elmer™ Life
Sciences, manufactured by Wallac Oy, Finland) described
in detail elsewhere [27].
Definition of peak values
For individual patients, the peak value for each peripheral
inflammatory marker was defined as the maximumBMC Neurology 2004, 4 http://www.biomedcentral.com/1471-2377/4/2
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measured value between presentation and 5 to 7 days.
Patients who died prior to 5 to 7 days, or for whom data
were missing, were therefore not assigned a peak value
and were excluded from further analysis.
Assessment of stroke severity and outcome
Stroke severity was assessed using the National Institutes
of Health Stroke Scale (NIHSS) score [29] at presentation
and 5 to 7 days. Functional status during the four weeks
preceding the index stroke was recorded using the modi-
fied Rankin score (mRS) [30] and Barthel index (BI) [31]
at presentation. Subsequent functional outcome was
assessed using the mRS and BI at 3 and 12 months,
derived either directly from evaluation of the patient or
discussion with carers and relatives, or by telephone.
Patients were contacted prior to the 3 and 12 month fol-
low up periods for arrangement of hospital or home visits
where necessary. All-cause mortality was recorded from
death certificates and hospital records.
Measurement of CT brain infarct volume
A second CT brain scan for volumetric analysis was per-
formed at 5 to 7 days, in order to minimise the "fogging"
effect seen in the second to third weeks after ischaemic
stroke [32]. Five to seven day CT brain scans and plasma
sampling were performed on the same day, except in five
cases where plasma was sampled, and CT scans per-
formed, within 24 hours of each other.
The area of visible recent infarction on each digitised slice
was traced manually with a cursor, the volume of infarc-
tion was automatically calculated by the scanner volume-
try program based on the areas measured, slice thickness
and number of slices. For each 5 to 7 day scan with visible
recent infarction, the mean of five observers' (CJS, HCAE,
CML and two consultant neuroradiologists; DGH and
IWT) independent infarct volume measurement was
determined.
Statistical analysis
Pre-determined primary analyses were the association
between peak plasma IL-6 concentration in the first week
of ischaemic stroke, with either CT brain infarct volume,
or mRS at 3 months. Secondary analyses explored the rela-
tionships between (1) peak plasma IL-6 concentration
with stroke severity, BI at 3 months or outcome at 12
months, and (2) other peripheral inflammatory markers
in the first week of ischaemic stroke and stroke severity,
CT brain infarct volume or clinical outcome.
For the pre-determined primary analyses, significance was
set at the 0.05 level. Data from the large number of sec-
ondary analyses are descriptive only, and used for the pur-
pose of hypothesis generation. Statistical analyses were
performed using SPSS® for Windows, version 10. Categor-
ical data were summarised as frequencies and percentages.
Continuous data were summarised as median (mini-
mum, maximum). Non-parametric analyses were used
throughout as the inflammatory markers were not nor-
mally distributed, and outcome measures were ordinal
scales. Use of non-parametric methods allowed extension
of scoring for outcome scales to incorporate death as the
"worst outcome" possible. This prevented bias from exclu-
sion of patients who died during study follow up. The
relationship between inflammatory markers and outcome
measures was determined using Spearman rank correla-
tion. The Kaplan-Meier technique and log-rank test were
applied in analysis of survival for patients with values
above and below the median of peak plasma IL-6
concentration.
Results
Thirty-seven patients with ischaemic stroke were recruited
between April 2000 and January 2001. Baseline character-
istics and medications for the 37 patients at entry are pre-
sented in Table 1. Median (minimum, maximum) time
from onset of stroke symptoms to recruitment was 5 (1.5
to 11.75) hours. Stroke characteristics and outcome meas-
ures are presented in Table 2. The number of patients at
each visit is outlined in Figure 1. Two patients had docu-
mented infections (both respiratory), and one, a proven
myocardial infarction within the six weeks preceding their
Table 1: Baseline characteristics and medications during study 
period (n = 37 acute ischaemic stroke patients at entry)
Mean age (SD) (years) 69.0 (13.1)
Male 24 (65%)
Caucasian 37 (100%)
Body mass index* (kg/m2) 26 (18,41)
Vital signs at presentation
Systolic blood pressure* (mm Hg) 152 (60, 232)
Diastolic blood pressure* (mm Hg) 83 (40, 146)
Aural temperature* (°C) 36.4 (34.8, 38.0)
Conventional vascular risk factors
Current or former smoker 26 (70%)
Smoking history unknown 1 (3%)
Previous stroke 7 (19%)
Hypertension 24 (65%)
Atrial fibrillation 8 (22%)
Diabetes mellitus 3 (8%)
Ischaemic heart disease 8 (22%)
Medications preceding or during study period
Paracetamol during first week 21 (57%)
Paracetamol during first week unknown 1 (3%)
Statins 21 (57%)
Antiplatelet agents 33 (89%)
Warfarin 4 (11%)
ACE-I or A-II receptor antagonist 10 (27%)
data shown as n (%) or *median (minimum, maximum) ACE-I: 
angiotensin converting enzyme inhibitor A-II: angiotensin-IIBMC Neurology 2004, 4 http://www.biomedcentral.com/1471-2377/4/2
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index stroke. A further 7 had definite infections (four res-
piratory, two urinary and one peripheral cannula site),
within the first week after the index stroke. One other
patient developed sepsis during the first week, with no
focus identified. Three patients died prior to the 5 to 7 day
assessment (including the patient with the preceding
myocardial infarction) leaving 34 patients with peak val-
ues of plasma IL-6, CRP, cortisol and aural temperature
for analysis. Peak WBC count values were available in 32,
and peak ESR in 27 of these patients. Of the fourteen
patients (38%) who died by 12 months, causes of death
were certified as index stroke in eight, recurrent stroke in
one, sepsis in three, pulmonary embolus in one, and left
ventricular failure secondary to preceding myocardial inf-
arction in another.
Peak plasma IL-6 concentration and outcome
In the primary analyses, peak plasma IL-6 concentration
correlated significantly with CT brain infarct volume and
mRS at 3 months (Figure 2). Exclusion of patients with
infection within the 6 weeks preceding, or one week fol-
lowing stroke did not materially affect these relationships
(CT brain infarct volume: r = 0.62, p = 0.006; mRS: r =
0.62, p = 0.002). Peak plasma IL-6 concentration also cor-
related (p < 0.001) with stroke severity at 5 to 7 days (r =
0.66), BI at 3 months (r = -0.74), mRS at 12 months (r =
0.77) and BI at 12 months (r = -0.77). As above, exclusion
of patients with infection did not materially alter these
findings (stroke severity at 5 to 7 days: r = 0.54, p = 0.006;
mRS at 12 months: r = 0.67, p = 0.001; BI at 3 months: r
= -0.64, p = 0.001; BI at 12 months: r = -0.63, p = 0.003).
As shown in Figure 3, peak plasma IL-6 concentration
above the sample median (30.5 pg/ml) was associated
with increased mortality at 12 months (p = 0.0011, log-
rank test).
Peak plasma CRP, ESR, WBC count, plasma cortisol, aural 
temperature and outcome
Correlation coefficients are presented in Table 3. Strong
associations were apparent for peak plasma CRP concen-
tration and peak WBC count in particular, with weaker
correlations for peak plasma cortisol concentration, ESR
and aural temperature. Exclusion of the patients with
infection did not materially alter these findings (data not
shown).
Table 2: Stroke characteristics and outcome measures (n = 37 
patients with acute ischaemic stroke at entry).
OCSP subtype
Total Anterior Circulation Syndrome 16 (43%)
Partial Anterior Circulation Syndrome 14 (38%)
Lacunar Syndrome 5 (14%)
Posterior Circulation Syndrome 2 (5%)
Left hemisphere infarcts 21 (57%)
Infarct volume* (cm3) n = 28 34.3 (0.6, 294.8)
NIHSS score*
Presentation (n = 37) 13 (3, 24)
5 to 7 day survivors (n = 34) 11 (1,39)
3 month survivors (n = 24) 5 (0,17)
12 month survivors (n = 19) 3 (0,17)
BI*
Presentation (n = 37) 100 (20,100)
3 month survivors (n = 26) 77.5 (0,100)
12 month survivors (n = 19) 90 (10,100)
mRS*
Presentation (n = 37) 0 (0,4)
3 month survivors (n = 26) 3 (0,5)
12 month survivors (n = 19) 3 (0,5)
data shown as n (%) or *median (minimum, maximum) mRS and BI at 
presentation are for the four weeks preceding the index stroke. Two 
patients withdrew at 3 months, BI, mRS obtained by telephone in 1 
patient. NIHSS score not available in one other patient at 3 months 
(declined examination). Two further patients had withdrawn at 12 
months (no NIHSS, BI, mRS available).
Study profile Figure 1
Study profile.
n=37 at study entry
n=34 alive and in 
study at 5 to 7 days
n=25 alive and in
study at 3 months
n=19 alive and in 
study at 12 months
3 died
7 died
2 withdrew
4 died
2 withdrewBMC Neurology 2004, 4 http://www.biomedcentral.com/1471-2377/4/2
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Relationship between peak plasma IL-6 concentration in the first week after ischaemic stroke and (a) CT infarct volume (n =  28) (b) mRS at 3 months (n = 33) Figure 2
Relationship between peak plasma IL-6 concentration in the first week after ischaemic stroke and (a) CT infarct volume (n = 
28) (b) mRS at 3 months (n = 33).
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Discussion
In the present study, we report that peak plasma IL-6 con-
centration in the first week of ischaemic stroke correlated
significantly with CT brain infarct volume at 5 to 7 days,
and clinical outcome at 3 months. Secondary analyses
also demonstrated strong associations between peak
plasma IL-6 and stroke severity, clinical outcome, or mor-
tality at 12 months. In keeping with these findings, other
peripheral markers of inflammation, including peak
plasma CRP, WBC count, ESR or plasma cortisol, were
associated with severity of stroke, CT brain infarct volume
or clinical outcome.
We reasoned that a good estimate of the magnitude of the
peripheral inflammatory response would be obtained by
taking the peak value of measurements within the first 24
hours of stroke, or at the end of the first week. We accept
that it is difficult to determine the true peak without con-
tinuous or multiple serial measurements. Furthermore,
only patients with data at all timepoints, and those surviv-
ing to day 5 to 7 could be included in analysis of peak val-
ues, therefore excluding patients that died within the first
week who may have had the most severe strokes. Previous
studies have reported peak values of serum IL-6 within the
first 10 days of stroke [13,15,18,33], but only two related
peak IL-6 to outcome measures, with neither defining pri-
mary analyses. Our data confirm the strong correlation
between peak serum IL-6 with CT infarct volume or stroke
severity [13,15]. We have extended these findings by dem-
onstrating, for the first time, strong correlations between
peak plasma IL-6 with measures of clinical outcome at 3
and 12 months. Furthermore, to our knowledge, we are
the first to report association between individual peak val-
ues of plasma CRP concentration, ESR or WBC count
within the first week of ischaemic stroke, and CT brain inf-
arct volume or outcome.
We did not exclude stroke patients with preceding or con-
current inflammatory conditions, as it may be argued that
findings are more useful if applicable to a generalised
population of patients, and that a systemic inflammatory
response to infection might contribute to poor outcome.
We may have underestimated the number of our patients
with infection, as we did not apply predetermined criteria
for defining, or investigating, infectious episodes. How-
ever, this also applies to previous studies of inflammation
and stroke where patients with infection were said to have
been excluded. Nevertheless, after performing post-hoc
analysis of our patients, excluding those with inflamma-
tory conditions in the six weeks preceding, or during the
first week of index stroke, correlations between peak
plasma IL-6, CRP or WBC count and outcome were only
moderately reduced.
The question arises as to whether IL-6 might directly con-
tribute to infarct pathogenesis, or is simply a marker of
CNS, or indeed other, inflammatory injury. On the one
hand, IL-6 has several pro-inflammatory effects [10,34-
37] which may contribute to the induction and evolution
of early inflammatory injury in the brain and its vascula-
ture. Furthermore, IL-6 is up-regulated by the proinflam-
matory cytokines interleukin-1β (IL-1β) and tumour
necrosis factor-α (TNF-α) [38]. In experimental cerebral
ischaemia, there is considerable evidence implicating IL-
1β in cerebral injury [39], although TNF-α may have both
deleterious and protective effects [40]. On the other hand,
IL-6 also has neurotrophic [41], and anti-inflammatory
effects [42] which may also be important after cerebral
ischaemia.
An important consideration is whether peripheral mark-
ers of inflammation relate to outcome independent of
stroke severity or brain infarct volume. IL-6 concentration
independently predicts early neurological deterioration
[14], and CRP concentration independently predicts sur-
vival, after ischaemic stroke [22,24-26]. We could not use
a multifactorial model to address whether peak plasma IL-
6 concentration related to outcome independently of
stroke severity or infarct size due to the limitation of our
sample size and insufficient power.
Twelve-month Kaplan-Meier survival curve for patients with  peak plasma IL-6 concentration less than, or greater than, the  sample median (30.5 pg/ml, n = 34) Figure 3
Twelve-month Kaplan-Meier survival curve for patients with 
peak plasma IL-6 concentration less than, or greater than, the 
sample median (30.5 pg/ml, n = 34).
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Despite the ability of IL-6 to induce fever or activate the
HPA axis, peak plasma IL-6 concentration only correlated
weakly with peak aural temperature or peak plasma
cortisol concentration (data not shown). Peak aural tem-
perature correlated weakly with brain infarct volume,
stroke severity or outcome, in contrast to previous studies
[23,43]. However, it is unclear from these previous reports
how many patients received antipyretics in relation to
measurements of temperature. In our study, a high pro-
portion of stroke patients received aspirin (300 mg), para-
cetamol, or both, in the first week of stroke, which may
have affected observed aural temperature readings. Peak
plasma cortisol concentration correlated modestly with
CT brain infarct volume, stroke severity or outcome, in
agreement with previous studies [19,44,45].
Conclusion
We have demonstrated significant correlations between
peak plasma IL-6 in the first week of ischaemic stroke with
both brain infarct volume and outcome at 3 months. Sec-
ondary analyses supported the relationship between
peripheral inflammatory markers and both the extent of
tissue injury, and clinical outcome to 12 months. Periph-
eral inflammatory markers may provide useful prognostic
information in patients with acute ischaemic stroke, and
pharmacological modulation of the inflammatory
response may provide the basis for novel acute neuropro-
tective therapies for use in patients with cerebral
ischaemia.
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